Saturday, October 1, 2022


Biotechnology News Magazine

Neuraxpharm Pursues Growth Strategy for Business in Switzerland

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Neuraxpharm Group (Neuraxpharm) ignites the next level of their business in Switzerland to leverage the full potential of the important pharmaceutical market.

After having laid the groundwork for its Swiss business in the recent past, Neuraxpharm reinforces its commitment to the market with today’s appointment of Jörg Gärtner as Country Manager for Switzerland. As experienced executive, Jörg Gärtner will focus on advancing Neuraxpharm as central nervous system (CNS) specialist in the Swiss market.

Switzerland represents an attractive pharmaceutical market in Europe due to its outstanding public health system and high purchasing power. Neuraxpharm taps into this market potential through its product offerings in CNS medication. The company will leverage its CNS expertise to provide access to suitable products out of its extensive portfolio including the recently acquired Buccolam® for emergency treatment of children and adolescents with epilepsy. Neuraxpharm entered the market through the acquisition of S.T.U., a leading Swiss-based distributor of cannabidiol (CBD) consumer products in 2019. Within the next months, Neuraxpharm furthermore plans to launch its medical cannabis portfolio to answer the increasing demand in the booming market.

With Jörg Gärtner, Neuraxpharm can rely on a dedicated pharmaceutical leader with highly relevant market expertise. In over 25 years of experience in the pharmaceutical industry, he gained profound knowledge of different countries, companies, and various therapeutic indications. Jörg Gärtner has a strong track record in successfully launching innovative products in competitive markets such as Germany, Austria and Switzerland. At Neuraxpharm he will utilize this knowledge to further expand the company’s market share in Switzerland and ensure the successful extension of the product portfolio for example with medical cannabis.

Jörg Gärtner joins Neuraxpharm from Almirall, where he most recently served as Business Leader Neurology in the CHAT area. Prior to his appointment as Business Leader, he was Head of Global Marketing for Sativex®. Jörg Gärtner was Brand Lead/Product Manager for Tecfidera® at Biogen Switzerland from 2012 to 2016, having previously held positions in product management at Roche Pharma Germany from 1996 to 2012. He started his career as a Primary Care Sales Representative at Lilly Deutschland from 1992 to 1996 and holds a master’s in international economy from Paris-Dauphine University and a master’s in general management from the Technical University of Berlin.

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, stated: “The Swiss market is of high strategic relevance for Neuraxpharm. After entering the market relatively recently through the acquisition of S.T.U. and its CBD portfolio, we are now very confident that with Jörg Gärtner we will successfully take our Swiss business to the next level. With his vast experience and entrepreneurial mindset, Jörg is best suited to leverage growth opportunities in the CNS and medical cannabis markets.”

Jörg Gärtner, newly appointed Country Manager for Switzerland, added: “I am excited to join Neuraxpharm as Country Manager. Neuraxpharm is in the perfect position to successfully expand in the Swiss market – in CNS products and beyond. I look forward to working with my new team and to making available my expertise both in the pharmaceutical industry as well as in Switzerland.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine